Search Results - "van den Bogaert, W"

The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 “boost versus no boost” trial by Poortmans, P.M., Collette, L., Bartelink, H., Struikmans, H., Van den Bogaert, W.F., Fourquet, A., Jager, J.J., Hoogenraad, W., Müller, R.-P., Dubois, J.-B., Bolla, M., Van Der Hulst, M., Wárlám-Rodenhuis, C.C., Pierart, M., Horiot, J.-C.

“…To investigate the impact of the boost dose to the primary tumour bed in the framework of breast conserving therapy on local control, cosmetic results,…”
Get full text

Suicidal sodium nitrite intoxication: a case report focusing on the postmortem findings and toxicological analyses—review of the literature by Andelhofs, D., Van Den Bogaert, W., Lepla, B., Croes, K., Van de Voorde, W.

“…Sodium nitrite (NaNO 2 ) is an inorganic compound that is commonly used as a preservative (E250) in the fish and meat industry. When ingested, sodium nitrite…”
Get full text

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy by Horiot, J C, Le Fur, R, N'Guyen, T, Chenal, C, Schraub, S, Alfonsi, S, Gardani, G, Van Den Bogaert, W, Danczak, S, Bolla, M

“…EORTC protocol 22791 compared once daily fractionation (CF) of 70 Gy in 35-40 fractions in 7-8 weeks, to pure hyperfractionation (HF) of 80.5 Gy in 70…”
Get more information

Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project by Bentzen, Søren M., Heeren, Germaine, Cottier, Brian, Slotman, Ben, Glimelius, Bengt, Lievens, Yolande, van den Bogaert, Walter

“…Adequate and equitable access to radiotherapy (RT) must be a reasonable health care goal for the EU. However, there are large variations among the EU countries…”
Get full text

Time-dose factors in radiotherapy: a review of the human data by Thames, H D, Bentzen, S M, Turesson, I, Overgaard, M, Van den Bogaert, W

“…The values for alpha/beta (fractionation sensitivity, or recovery capacity) for early and late reactions in human normal tissues are consistent with results…”
Get more information

In Vivo Antitumour Effect of Combretastatin A-4 Phosphate Added to Fractionated Irradiation by AHMED, B, LANDUYT, W, GRIFFIOEN, A. W, VAN OOSTEROM, A, VAN DEN BOGAERT, W, LAMBIN, P

“…Background: The study aimed at evaluating the potential benefit from a combination of fractionated ionising radiation with the vascular-targeting compound…”
Get full text

Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? by Vrieling, C, Collette, L, Fourquet, A, Hoogenraad, W.J, Horiot, J.-C, Jager, J.J, Bing Oei, S, Peterse, H.L, Pierart, M, Poortmans, P.M, Struikmans, H, Van den Bogaert, W, Bartelink, H

“…The aim of this study was to identify patient-, tumour- or treatment-related factors associated with young age that might explain the higher risk of…”
Get full text

The utility of SPECT in determining the relationship between radiation dose and salivary gland dysfunction after radiotherapy by VAN ACKER, F, FLAMEN, P, LAMBIN, P, MAES, ANNELIES, KUTCHER, G J, WELTENS, C, HERMANS, R, BAETENS, J, DUPONT, P, RIJNDERS, A, MAES, ALEX, VAN DEN BOGAERT, W, MORTELMANS, L

“…Salivary gland scintigraphy (SGS) is used to depict salivary gland dysfunction after radiotherapy (RT). The aim of this study was to investigate the utility of…”
Get full text

6LBA The benefit of regional irradiation in stage I–III breast cancer: 10 years results of the EORTC ROG and BCG phase III trial 22922/10925 by Struikmans, H, Collette, S, Van den Bogaert, W, Kirkove, C, Budach, V, Maingon, P, Valli, M.C, Fourquet, A, Bartelink, H, Poortmans, P

Get full text

OC-0523: Lymph node RT improves survival in breast cancer: 10 years results of the EORTC ROG and BCG phase III trial 22922/10925 by Poortmans, P, Struikmans, H, Collette, S, Kirkove, C, Budach, V, Maingon, P, Valli, M.C, Fourquet, A, Van den Bogaert, W, Bartelink, H

Get full text

CT findings in osteoradionecrosis of the mandible by HERMANS, R, FOSSION, E, IOANNIDES, C, VAN DEN BOGAERT, W, GHEKIERE, J, BAERT, A. L

Get full text

The requirements of a specialist breast unit by EUSOMA

Get full text

Prevalent breast cancer patients with a homozygous mutant status for CYP2D64: response and biomarkers in tamoxifen users by Dieudonné, A. S, Lambrechts, D, Claes, B, Vandorpe, T, Wildiers, H, Timmerman, D, Billen, J, Leunen, K, Amant, F, Berteloot, P, Smeets, A, Paridaens, R, Weltens, C, Van Limbergen, E, Van den Bogaert, W, Vergote, I, Van Huffel, S, Christiaens, M. R, Neven, P

“…Retrospective studies suggest that single nucleotide polymorphisms in the cytochrome P450 2D6 (CYP2D6) gene predict reduced tamoxifen metabolism, better…”
Get full text

A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood by Aerts, J., Wynendaele, W., Paridaens, R., Christiaens, M.-R., van den Bogaert, W., van Oosterom, A.T., Vandekerckhove, F.

“…Background The detection of occult carcinoma cells in patients with breast cancer has been shown to predict disease recurrence and metastasis Materials and…”
Get full text

Quality assurance of EORTC trial 22922/10925 investigating the role of internal mammary—medial supraclavicular irradiation in stage I-III breast cancer: the individual case review by Poortmans, P., Kouloulias, V.E., Venselaar, J.L., Struikmans, H., Davis, J.B., Huyskens, D., van Tienhoven, G., Hurkmans, C., Mijnheer, B., Van den Bogaert, W.

“…To assess consistency among participants in an European Organisation for Research and Treatment of Cancer (EORTC) phase III trial randomising between…”
Get full text

Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer by Neven, P., Van Calster, B., Van den Bempt, I., Van Huffel, S., Van Belle, V., Hendrickx, W., Decock, J., Wildiers, H., Paridaens, R., Amant, F., Leunen, K., Berteloot, P., Timmerman, D., Van Limbergen, E., Weltens, C., Van den Bogaert, W., Smeets, A., Vergote, I., Christiaens, M. R., Drijkoningen, M.

“…Background: The negative association between the oestrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER-2) in breast cancer travels in…”
Get full text

WE‐C‐AUD B‐10: Which Patients Benefit From Prospective Gating in Treatment for Loco‐Regional Breast Irradiation — a Radiobiological Assessment by Erven, K, Hrbacek, J, Petillion, S, Defraene, G, Weltens, C, Van den Bogaert, W, Van den Heuvel, F

“…Purpose: To determine a selection procedure based on radiobiological parameters to triage patients that benefit maximally from the use of free breathing gating…”
Get full text

No age limit for radical radiotherapy in head and neck tumours by Pignon, T., Horiot, J.-C., Van den Bogaert, W., Van Glabbeke, M., Scalliet, P.

“…The elderly are often treated less aggressively in an attempt to preserve their quality of life with regards to toxicity. However, there are few data regarding…”
Get full text

The prognostic value of FMISO and FDG pet in locally advanced head and neck cancer (HNC) by Dirix, P, Plessers, L, Slagmolen, F, Stroobants, S, Van den Bogaert, W, Nuyts, S

Get full text

A CASE SERIES OF EMBRYONAL RHABDOMYOSARCOMA OF THE HEAD AND NECK IN ADULTS by Wagemans, J., Beuselinck, B., Nuyts, S., Sciot, R., Delaere, P., Vander Poorten, V., Dumez, H., Hermans, R., Schöffski, P., Van den Bogaert, W., Jorissen, M., Clement, P.M.J.

“…Embryonal rhabdomyosarcoma (RMS) is a rare malignant mesenchymal tumour that is believed to arise from cells committed to a skeletal muscle lineage. The head…”
Get full text